Alert detail

FDA Approval: JAKAFI XR (RUXOLITINIB) — Type 5 - New Formulation or New Manufacturer

Policy ID: FDA-NDA217180Specialty: HematologyAdded: 7/24/2026Effective: May 1, 2026federal register

Low

What changed

Oral ruxolitinib ER tablets route to Part D; no J-code applies.

Who’s affected: Hematology billing teams · Effective: May 1, 2026

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plans Create a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Hematology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Hematology— the week’s changes and deadlines, delivered to your inbox. No account required.